FDA steers J&J/Legend CAR-T to a quick decision as partners prep a looming showdown with Bristol Myers, bluebird
Just days after investigators posted a jaw-dropping set of positive updated data for the BCMA CAR-T cilta-cel — or JNJ-4528 — J&J’s partners at Legend are back with the news that the FDA is putting their application for the multiple myeloma treatment in the fast lane and speeding it to a fall regulatory decision deadline. And that would put them right behind the newly launched BCMA drug Abecma from Bristol Myers Squibb and bluebird, widely considered now as a runner-up on efficacy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,900+ biopharma pros reading Endpoints daily — and it's free.